These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

70 related articles for article (PubMed ID: 24743199)

  • 1. [Effect of oral dexamethasone given 24 hours previously on docetaxel-induced edema: a retrospective study].
    Kato A; Masuda N; Makihara K; Ueno H; Hirohata K; Yamauchi K; Yasojima H; Mizutani M; Yamamura J; Komori K
    Gan To Kagaku Ryoho; 2014 Feb; 41(2):211-4. PubMed ID: 24743199
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Single premedication dose of dexamethasone 20 mg IV before docetaxel administration.
    Chouhan JD; Herrington JD
    J Oncol Pharm Pract; 2011 Sep; 17(3):155-9. PubMed ID: 20447949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subjective and objective assessment of edema during adjuvant chemotherapy for breast cancer using taxane-containing regimens in a randomized controlled trial: The National Surgical Adjuvant Study of Breast Cancer 02.
    Ohsumi S; Shimozuma K; Ohashi Y; Takeuchi A; Suemasu K; Kuranami M; Ohno S; Watanabe T
    Oncology; 2012; 82(3):131-8. PubMed ID: 22433221
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility study of docetaxel with cyclophosphamide as adjuvant chemotherapy for Japanese breast cancer patients.
    Takabatake D; Taira N; Hara F; Sien T; Kiyoto S; Takashima S; Aogi K; Ohsumi S; Doihara H; Takashima S
    Jpn J Clin Oncol; 2009 Aug; 39(8):478-83. PubMed ID: 19491086
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study.
    von Minckwitz G; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; Untch M
    J Clin Oncol; 2010 Apr; 28(12):2015-23. PubMed ID: 20308671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the effects and adverse drug reactions of low-dose dexamethasone premedication with weekly docetaxel.
    Kang RY; Yoo KS; Han HJ; Lee JY; Lee SH; Kim DW; Lee YJ
    Support Care Cancer; 2017 Feb; 25(2):429-437. PubMed ID: 27687722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of Perioperative Docetaxel-induced Limb Edema on Health-related Quality of Life in Patients with Early-stage Breast Cancer: A Prospective Observational Study.
    Matsumoto K; Morimoto Y; Wakatsuki J; Sakuma D; Mukouyama K; Inoue M; Kimura A; Hirosawa I; Watanabe K
    Yakugaku Zasshi; 2024; 144(6):685-690. PubMed ID: 38825477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of steroids on edema, ecchymosis, and intraoperative bleeding in rhinoplasty.
    Kargi E; Hoşnuter M; Babucçu O; Altunkaya H; Altinyazar C
    Ann Plast Surg; 2003 Dec; 51(6):570-4. PubMed ID: 14646651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A retrospective comparison of docetaxel and paclitaxel for patients with advanced or recurrent esophageal cancer who previously received platinum-based chemotherapy.
    Mizota A; Shitara K; Kondo C; Nomura M; Yokota T; Takahari D; Ura T; Muro K
    Oncology; 2011; 81(3-4):237-42. PubMed ID: 22094594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients.
    Pierga JY; Delaloge S; Espié M; Brain E; Sigal-Zafrani B; Mathieu MC; Bertheau P; Guinebretière JM; Spielmann M; Savignoni A; Marty M
    Breast Cancer Res Treat; 2010 Jul; 122(2):429-37. PubMed ID: 20480225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial.
    Joensuu H; Bono P; Kataja V; Alanko T; Kokko R; Asola R; Utriainen T; Turpeenniemi-Hujanen T; Jyrkkiö S; Möykkynen K; Helle L; Ingalsuo S; Pajunen M; Huusko M; Salminen T; Auvinen P; Leinonen H; Leinonen M; Isola J; Kellokumpu-Lehtinen PL
    J Clin Oncol; 2009 Dec; 27(34):5685-92. PubMed ID: 19884557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A pilot study of adjuvant nanoparticle albumin-bound (nab) paclitaxel and cyclophosphamide, with trastuzumab in HER2-positive patients, in the treatment of early-stage breast cancer.
    Yardley D; Burris H; Peacock N; Raefsky E; Melnik M; Inhorn R; Shipley D; Hainsworth J
    Breast Cancer Res Treat; 2010 Sep; 123(2):471-5. PubMed ID: 20658263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A lower dose of docetaxel at 60 mg/m(2) could be continued longer for controlling peripheral edema in patients with metastatic breast cancer.
    Hosonaga M; Ito Y; Tokudome N; Takahashi S; Iwase T; Hatake K
    Breast Cancer; 2012 Oct; 19(4):329-34. PubMed ID: 21863309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Provision of information by pharmacists regarding the effective timing of co-administration of first-generation serotonin receptor antagonists and dexamethasone for chemotherapy-induced nausea and vomiting in patients receiving Doxorubicin and cyclophosphamide chemotherapy for breast cancer].
    Nomura H; Kawakami H; Shimizu H; Imi K; Ito H; Isaka H; Shinohara T; Nagai S; Imoto S
    Gan To Kagaku Ryoho; 2012 Jan; 39(1):75-9. PubMed ID: 22241355
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
    Ichinose I; Hamada Y; Mitsuyama S; Ishikawa E; Ikeda T; Kobayashi S; Horikoshi N; Tamura K
    Chemotherapy; 2008; 54(5):379-85. PubMed ID: 18758179
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
    Roché H; Fumoleau P; Spielmann M; Canon JL; Delozier T; Serin D; Symann M; Kerbrat P; Soulié P; Eichler F; Viens P; Monnier A; Vindevoghel A; Campone M; Goudier MJ; Bonneterre J; Ferrero JM; Martin AL; Genève J; Asselain B
    J Clin Oncol; 2006 Dec; 24(36):5664-71. PubMed ID: 17116941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial comparing granulocyte colony-stimulating factor to leridistim in the prevention of neutropenic complications in breast cancer patients treated with docetaxel/doxorubicin/cyclophosphamide: results of the BCIRG 004 trial.
    Nabholtz JM; Cantin J; Chang J; Guevin R; Patel R; Tkaczuk K; Vodvarka P; Lindsay MA; Reese D; Riva A; Mackey J
    Clin Breast Cancer; 2002 Oct; 3(4):268-75. PubMed ID: 12425755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
    Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
    Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized study of docetaxel and dexamethasone with low- or high-dose estramustine for patients with advanced hormone-refractory prostate cancer.
    Nelius T; Klatte T; Yap R; Kalinski T; Röpke A; Filleur S; Allhoff EP
    BJU Int; 2006 Sep; 98(3):580-5. PubMed ID: 16925757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study.
    Untch M; Rezai M; Loibl S; Fasching PA; Huober J; Tesch H; Bauerfeind I; Hilfrich J; Eidtmann H; Gerber B; Hanusch C; Kühn T; du Bois A; Blohmer JU; Thomssen C; Dan Costa S; Jackisch C; Kaufmann M; Mehta K; von Minckwitz G
    J Clin Oncol; 2010 Apr; 28(12):2024-31. PubMed ID: 20308670
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.